Skip to Main Content
Contribute Try STAT+ Today

Good morning, everyone, and how are you today? We are just fine, thank you, especially since a shiny sun and cool breeze are enveloping the Pharmalot campus this morning. This also makes for a lovely day to take a few moments to watch the shortest of our short people matriculate among schoolhouses. So please excuse us while we take a midday break to celebrate. Meanwhile, here are some items of interest to keep you focused. Hope your day goes well and, of course, do keep in touch …

Novartis rejected overtures from President Trump to increase jobs in the U.S., citing work visa restrictions for foreign nationals as a reason, according to Swissinfo. “This makes the country a less attractive location for investment,” Novartis chief executive Joe Jimenez explained. “By contrast, Switzerland and Europe will become more attractive.” In the U.S., the company currently has more than 22,000 employees.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
  • Jimeniz is blowing smoke up Trump’s tail pipe. For every H1B visa foreign pharma worker there are qualified Americans standing in line. As my wife used to joke “it’s Swiss!”

Comments are closed.